Grifols (GIFLF) EBT Growth (1y) (2011 - 2025)
Powered by 
Analysis
Grifols (GIFLF) EBT Growth (1y) (2011 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 76.53% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -522.15% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 8.48% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 0.60% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 88.92% |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 6.23% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 530.43% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -82.20% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 13.58% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 13.58% |
| Dec 31, 2022 | 260.46% |
| Dec 31, 2021 | -8.37% |
| Dec 31, 2020 | -132.11% |
| Mar 31, 2020 | 70.84% |
| Dec 31, 2019 | -7.46% |
| Mar 31, 2019 | -26.14% |
| Dec 31, 2018 | -3.93% |
| Jun 30, 2018 | -0.38% |
| Mar 31, 2018 | 12.63% |
| Dec 31, 2017 | 3,021.96% |
| Jun 30, 2017 | 19.88% |
| Mar 31, 2017 | -37.36% |
| Dec 31, 2016 | 173.14% |
| Sep 30, 2016 | -2.83% |
| Jun 30, 2016 | 0.98% |
| Mar 31, 2016 | 16.68% |
| Dec 31, 2015 | -114.87% |
| Sep 30, 2015 | 52.00% |
| Jun 30, 2015 | 140,557.99% |